124 related articles for article (PubMed ID: 16732709)
1. Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
Doggrell SA
Expert Opin Pharmacother; 2006 Jun; 7(9):1229-33. PubMed ID: 16732709
[TBL] [Abstract][Full Text] [Related]
2. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Nissen SE; Wolski K; Topol EJ
JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
[TBL] [Abstract][Full Text] [Related]
3. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
4. Selling safety--lessons from muraglitazar.
Brophy JM
JAMA; 2005 Nov; 294(20):2633-5. PubMed ID: 16239638
[No Abstract] [Full Text] [Related]
5. Adverse events related to muraglitazar use in diabetes.
Parra D; Beckey C; Thomas T
JAMA; 2006 May; 295(17):1997-8; author reply 1998. PubMed ID: 16670403
[No Abstract] [Full Text] [Related]
6. Adverse events related to muraglitazar use in diabetes.
Najman DM
JAMA; 2006 May; 295(17):1997; author reply 1998. PubMed ID: 16670404
[No Abstract] [Full Text] [Related]
7. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
8. Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
Rubin CJ; Ledeine JM; Fiedorek FT
Diab Vasc Dis Res; 2008 Sep; 5(3):168-76. PubMed ID: 18777489
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Rubin CJ; Viraswami-Appanna K; Fiedorek FT
Diab Vasc Dis Res; 2009 Jul; 6(3):205-15. PubMed ID: 20368213
[TBL] [Abstract][Full Text] [Related]
10. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
[TBL] [Abstract][Full Text] [Related]
11. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
Cox SL
Drugs Today (Barc); 2005 Sep; 41(9):579-87. PubMed ID: 16341289
[TBL] [Abstract][Full Text] [Related]
12. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Charbonnel B
Lancet; 2009 Jul; 374(9684):96-8. PubMed ID: 19515412
[No Abstract] [Full Text] [Related]
13. Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
Rubin CJ; De Pril V; Fiedorek FT
Diab Vasc Dis Res; 2009 Apr; 6(2):120-32. PubMed ID: 20368202
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
15. Muraglitazar (Bristol-Myers Squibb/Merck).
Barlocco D
Curr Opin Investig Drugs; 2005 Apr; 6(4):427-34. PubMed ID: 15898350
[TBL] [Abstract][Full Text] [Related]
16. Molecule of the month. Muraglitazar.
Drug News Perspect; 2005 May; 18(4):284. PubMed ID: 16034485
[No Abstract] [Full Text] [Related]
17. The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Kalliora C; Drosatos K
J Cardiovasc Pharmacol; 2020 Nov; 76(5):514-526. PubMed ID: 33165133
[TBL] [Abstract][Full Text] [Related]
18. Is it safe to combine PPAR agonists? A lesson from muraglitazar.
Stulc T; Ceska R
Med Hypotheses; 2006; 67(3):669. PubMed ID: 16762511
[No Abstract] [Full Text] [Related]
19. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical inflammation revisited: muraglitazar and cardiovascular risk.
Yun AJ; Lee PY; Doux JD
Med Hypotheses; 2006; 66(4):855. PubMed ID: 16337749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
